دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Audio Summary
empty
doi : 10.1016/S0735-1097(21)00269-2
Volume 77, Issue 9, 9 March 2021, Page e223
no abstract
Contents
empty
doi : 10.1016/S0735-1097(21)00395-8
Volume 77, Issue 9, 9 March 2021, Pages e225-e228
no abstract
Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk
Martin B.LeonMDabMichael J.MackMDcRebecca T.HahnMDabVinod H.ThouraniMDdRajMakkarMDeSusheel K.KodaliMDaMaria C.AluMSabMahesh V.MadhavanMDabKatherine H.ChauMD, MSaMarkRussoMD, MSfSamir R.KapadiaMDgS. ChrisMalaisrieMDhDavid J.CohenMD, MSciPhilippBlankeMDjJonathon A.LeipsicMDjMathew R.WilliamsMDkJames M.McCabeMDlDavid L.BrownMDcVasilisBabaliarosMDmScottGoldmanMDnHoward C.HerrmannMDoWilson Y.SzetoMDoPhilippeGenereuxMDpAshishPershadMD, MSqMichaelLuPhDrJohn G.WebbMDjCraig R.SmithMDaPhilippePibarotDVM, PhDsfor thePARTNER 3 Investigators
doi : 10.1016/j.jacc.2020.12.052
Volume 77, Issue 9, 9 March 2021, Pages 1149-1161
In low surgical risk patients with symptomatic severe aortic stenosis, the PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis) trial demonstrated superiority of transcatheter aortic valve replacement (TAVR) versus surgery for the primary endpoint of death, stroke, or re-hospitalization at 1 year.
TAVR Versus SAVR in Aortic Stenosis: Long Journey, New Roadmap?
Bernard D.PrendergastMDabSimon R.RedwoodMDacTiffanyPattersonMDac
doi : 10.1016/j.jacc.2021.01.012
Volume 77, Issue 9, 9 March 2021, Pages 1162-1164
no abstract
10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction
SalvatoreBrugalettaMD, PhDa?JosepGomez-LaraMD, PhDb?LuisOrtega-PazMD, PhDaVictorJimenez-DiazMD, PhDcMarceloJimenezMDdPilarJiménez-QuevedoMD, PhDeRobertoDilettiMD, PhDfVicenteMainarMD, PhDgGianlucaCampoMD, PhDhAntonioSilvestroMDiJaumeMaristanyMD, PhDjXacobeFloresMD, PhDkLoretoOyarzabalMDbAntonioDe Miguel-CastroMDcAndrésI?iguezMD, PhDcAntonioSerraMD, PhDdLuisNombela-FrancoMD, PhDeAlfonsoIelasiMD, PhDiMaurizioTespiliMD, PhDiMattieLenzenMD, PhDfNievesGonzaloMD, PhDePascualBordesMDgMatteoTebaldiMDhSimoneBiscagliaMDhJuan JoseRodriguez-AriasMDaSoheilAl-ShaibaniMDfVictorArevalosMDaRafaelRomagueraMDbJoan AntoniGomez-HospitalMD, PhDbPatrick W.SerruysMD, PhDlmManelSabatéMD, PhDan
doi : 10.1016/j.jacc.2020.12.059
Volume 77, Issue 9, 9 March 2021, Pages 1165-1178
Outcomes data for a durable-polymer everolimus-eluting stent (EES) at extended long-term follow-up in patients with ST-segment elevation myocardial infarction (STEMI) are unknown.
Standing the Test of Time: A Device and Patient Perspective?
Donald E.CutlipMD
doi : 10.1016/j.jacc.2021.01.005
Volume 77, Issue 9, 9 March 2021, Pages 1179-1181
no abstract
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
R. ScottWrightMDaKausik K.RayMDb?Frederick J.RaalMD, PhDc?David G.KallendMBBSdMarkJarosPhDeWolfgangKoenigMDfgLawrence A.LeiterMDhUlfLandmesserMDiGregory G.SchwartzMD, PhDjAndrewFriedmanPharmDkPeter L.J.WijngaardPhDkLorenaGarcia CondeMDlJohn J.P.KasteleinMD, PhDmORION Phase III Investigators
doi : 10.1016/j.jacc.2020.12.058
Volume 77, Issue 9, 9 March 2021, Pages 1182-1193
Inclisiran is a double-stranded small interfering RNA that suppresses proprotein convertase subtilisin–kexin type 9 (PCSK9) translation in the liver, leading to sustained reductions in low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins with twice-yearly dosing.
Inclisiran: A Game Changer in a Changing Game??
VijayNambiMD, PhDabAliAghaMDb
doi : 10.1016/j.jacc.2021.01.008
Volume 77, Issue 9, 9 March 2021, Pages 1194-1196
no abstract
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation
JanSteffelMDaChristian T.RuffMD, MPHbOpheliaYinPhDcEugeneBraunwaldMDbJeong-GunParkPhDbSabina A.MurphyMPHbStuartConnollyMDdElliott M.AntmanMDbRobert P.GiuglianoMD, SMb
doi : 10.1016/j.jacc.2020.12.053
Volume 77, Issue 9, 9 March 2021, Pages 1197-1207
In the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial, the lower dose edoxaban regimen (LDER) and the higher dose edoxaban regimen (HDER) were noninferior to well-managed warfarin for stroke prevention in atrial fibrillation.
Low-Dose Anticoagulation for Atrial Fibrillation: When Is a Floor a Trap Door??
Jonathan L.HalperinMDEman R.RashedMD, PhD
doi : 10.1016/j.jacc.2021.01.024
Volume 77, Issue 9, 9 March 2021, Pages 1208-1210
no abstract
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function
Iris E.BeldhuisBScabPeder L.MyhreMD, PhDacMichaelBristowMD, PhDdBrianClaggettPhDaKevinDammanMD, PhDbJames C.FangMDeJerome L.FlegMDfSonjaMcKinlayMDgEldrin F.LewisMD, MPHaEileenO’MearaMDhBertramPittMDiSanjiv J.ShahMDjOrlyVardenyPharmD, MSkAdriaan A.VoorsMD, PhDbMarc A.PfefferMD, PhDaScott D.SolomonMDaAkshay S.DesaiMD, MPHa
doi : 10.1016/j.jacc.2020.12.057
Volume 77, Issue 9, 9 March 2021, Pages 1211-1221
Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization (HFH) but increased risk of worsening renal function (WRF). The prognostic implications of spironolactone-associated WRF in HFpEF patients are not well understood.
Ambulatory Worsening of Renal Function in Heart Failure With Preserved Ejection Fraction?
Peter A.McCulloughMD, MPHabcdeGelarehRahimiPhDbdKristen M.TecsonPhDbde
doi : 10.1016/j.jacc.2021.01.007
Volume 77, Issue 9, 9 March 2021, Pages 1222-1224
no abstract
Advanced Therapies for Ventricular Arrhythmias in Patients With Chagasic Cardiomyopathy: JACC State-of-the-Art Review
JorgeRomeroMDa?AlejandroVelascoMDa?Cristiano F.PisaniMD-PhDbIsabellaAlvizMDaDavidBricenoMDaJuan CarlosD?azMDaDomenico GiovanniDella RoccaMDcAndreaNataleMDacMariade Lourdes HiguchiMDbMauricioScanavaccaMD, PhDbLuigiDi BiaseMD-PhDac
doi : 10.1016/j.jacc.2020.12.056
Volume 77, Issue 9, 9 March 2021, Pages 1225-1242
Chagas disease is caused by infection from the protozoan parasite Trypanosoma cruzi. Although it is endemic to Latin America, global migration has led to an increased incidence of Chagas in Europe, Asia, Australia, and North America. Following acute infection, up to 30% of patients will develop chronic Chagas disease, with most patients developing Chagasic cardiomyopathy. Chronic Chagas cardiomyopathy is highly arrhythmogenic, with estimated annual rates of appropriate implantable cardioverter-defibrillator therapies and electrical storm of 25% and 9.1%, respectively. Managing arrhythmias in patients with Chagasic cardiomyopathy is a major challenge for the clinical electrophysiologist, requiring intimate knowledge of cardiac anatomy, advanced training, and expertise. Endocardial-epicardial mapping and ablation strategy is needed to treat arrhythmias in this patient population, owing to the suboptimal long-term success rate of endocardial mapping and ablation alone. We also describe innovative approaches to improve acute and long-term clinical outcomes in patients with refractory ventricular arrhythmias following catheter ablation, such as bilateral cervicothoracic sympathectomy and bilateral renal denervation, among others.
Managing Patients With Short-Term Mechanical Circulatory Support: JACC Review Topic of the Week
TimBalthazarMDaChristopheVandenbrieleMD, PhDabFrederik H.VerbruggeMD, PhDcdCorstiaanDen UilMD, PhDefAnnemarieEngstr?mMD, PhDefStefanJanssensMD, PhDaSteffenRexMD, PhDgBartMeynsMD, PhDhNicolasVan MieghemMD, PhDfSusannaPriceMD, PhDbTomAdriaenssensMD, PhDa
doi : 10.1016/j.jacc.2020.12.054
Volume 77, Issue 9, 9 March 2021, Pages 1243-1256
The use of mechanical circulatory support for patients presenting with cardiogenic shock is rapidly increasing. Currently, there is only limited and conflicting evidence available regarding the role of the Impella (a microaxial, continuous-flow, short-term, left or right ventricular assist device) in cardiogenic shock; further randomized trials are needed. Patient selection, timing of implantation, and post-implantation management in the cardiac intensive care unit are crucial elements for success. Particular challenges at the bedside include the practical management of anticoagulation, evaluation of correct device position, and the approach to use in a patient with signs of insufficient hemodynamic support. Profound knowledge of these issues is required to enable the maximal potential of the device. This review provides a comprehensive overview of the short-term assist device and describes a practical approach to optimize care for patients supported with the device.
How to Build an Antiracist Cardiovascular Culture, Community, and Profession
NinaWilliamsMDaMelanie S.SulistioMDbDavid E.WinchesterMD, MScChristineChenBAbLorrel E.B.ToftMDd
doi : 10.1016/j.jacc.2020.11.073
Volume 77, Issue 9, 9 March 2021, Pages 1257-1261
no abstract
Clinical Course of Pregnancy and Long-Term Follow-Up After Delivery in Hypertrophic Cardiomyopathy
Maria BeatriceMusumeciMDPaoloSpiritoMDMaria RosaConteMDRosaLilloMDEmmanuelaDevotoMDPietroFranciaMDDomitillaRussoMDMassimoVolpeMDLucaBoniMD, PhDCamilloAutoreMD
doi : 10.1016/j.jacc.2020.12.055
Volume 77, Issue 9, 9 March 2021, Pages 1262-1264
no abstract
Diagnostic Performance of the European Society of Cardiology 0/1-h Algorithms in Late Presenters
JasperBoeddinghausMDThomasNestelbergerMDPedroLopez-AyalaMDLucaKoechlinMDMichaelBuechiMDOscarMiroMDDagmar I.KellerMDMaria RubiniGimenezMDRaphaelTwerenboldMDChristianMuellerMDAPACE Investigators
doi : 10.1016/j.jacc.2021.01.004
Volume 77, Issue 9, 9 March 2021, Pages 1264-1267
no abstract
Food as Medicine: Prevention Is Better, but Could It Cure?
MuddassirMehmoodMD
doi : 10.1016/j.jacc.2020.11.078
Volume 77, Issue 9, 9 March 2021, Page 1267
no abstract
Reply: Food as Medicine: Prevention Is Better, but Could It Cure?
JunLiMD, PhDFrank B.HuMD, PhD
doi : 10.1016/j.jacc.2020.12.049
Volume 77, Issue 9, 9 March 2021, Pages 1267-1268
no abstract
Correction
empty
doi : 10.1016/j.jacc.2021.01.026
Volume 77, Issue 9, 9 March 2021, Pages 1269-1274
no abstract
Correction
empty
doi : 10.1016/j.jacc.2021.02.007
Volume 77, Issue 9, 9 March 2021, Page 1275
no abstract
Correction
empty
doi : 10.1016/j.jacc.2021.02.008
Volume 77, Issue 9, 9 March 2021, Page 1276
no abstract
